Pertuzumab biosimilar (biocad)

帕妥珠单抗生物类似药（biocad）

Report date: 2023/02/23 20:00:33

Base Information

Drug NamePertuzumab biosimilar (biocad)
Drug Alias NameBCD-178
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A